Filing Details

---

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No.  1)*

Aerpio Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

00810B105

(CUSIP Number)

Bart Dzikowski

Secretary of the Board

Novartis Bioventures Ltd.

Lichtstrasse 35

CH-4056 Basel, Switzerland

+41 61 324 3714

 (Name, Address and Telephone Number of Person

Authorized to Receive Notices and Communications)

June 28, 2018

(Date of Event Which Requires Filing of this Statement)

 

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

 

*	The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

 

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of section 18 of the Securities Exchange Act of 1934, as amended (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

---

CUSIP No. 00810B105

Schedule 13D

 

1	NAMES OF REPORTING PERSONS
	Novartis Bioventures Ltd.
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP			(a)	☐
				(b)	☐
3	SEC USE ONLY
4	SOURCE OF FUNDS (SEE INSTRUCTIONS)
	WC
5	CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)				☐
6	CITIZENSHIP OR PLACE OF ORGANIZATION
	Switzerland
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:		7	SOLE VOTING POWER
			0
		8	SHARED VOTING POWER
			5,805,550
		9	SOLE DISPOSITIVE POWER
			0
		10	SHARED DISPOSITIVE POWER
			5,805,550
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	5,805,550
12	CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)				☐
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
	14.95% (1)
14	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
	CO

 

(1)

Based upon 38,834,099 outstanding shares of common stock, par value $0.0001 per share, of Aerpio Pharmaceuticals, Inc. (the “Issuer”), as set forth in the Issuer’s Prospectus Supplement (which assumes no exercise of the underwriters’ option to purchase additional shares) filed with the Securities and Exchange Commission (the “SEC”) on June 26, 2018 pursuant to SEC Rule 424(b)(5).

 

CUSIP No. 00810B105

Schedule 13D

 

1	NAMES OF REPORTING PERSONS
	Novartis AG
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP			(a)	☐
				(b)	☐
3	SEC USE ONLY
4	SOURCE OF FUNDS (SEE INSTRUCTIONS)
	WC
5	CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)				☐
6	CITIZENSHIP OR PLACE OF ORGANIZATION
	Switzerland
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:		7	SOLE VOTING POWER
			0
		8	SHARED VOTING POWER
			5,805,550
		9	SOLE DISPOSITIVE POWER
			0
		10	SHARED DISPOSITIVE POWER
			5,805,550
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	5,805,550
12	CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)				☐
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
	14.95% (1)
14	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
	CO

 

(1)

Based upon 38,834,099 outstanding shares of common stock, par value $0.0001 per share, of the Issuer, as set forth in the Issuer’s Prospectus Supplement (which assumes no exercise of the underwriters’ option to purchase additional shares), filed with the SEC on June 26, 2018 pursuant to SEC Rule 424(b)(5).

 

CUSIP No. 00810B105

Schedule 13D

 

Item 1.

Security and Issuer.

 

This Amendment No. 1 (the “Amendment”) to the statement on Schedule 13D amends the Schedule 13D filed with the SEC on March 27, 2017 (the “Original Schedule 13D”) and relates to the common stock, par value $0.0001 per share (the “Common Stock”), of Aerpio Pharmaceuticals, Inc., a Delaware corporation (the “Issuer”).  The address of the Issuer’s principal executive office is 9987 Carver Road, Cincinnati, OH 45242.

 

On June 26, 2018, the Issuer filed a Prospectus Supplement with the Securities and Exchange Commission (the “SEC”) pursuant to SEC Rule 424(b)(5), in which it reported that it anticipated having 38,834,099 shares of Common Stock outstanding (which assumes no exercise of the underwriters’ option to purchase additional shares) following completion of the offering, which closed on June 28, 2018. As a result of the reported increase in the number of shares of Common Stock outstanding, the percentage of outstanding shares of Common Stock that the Reporting Persons may be deemed to beneficially own was reduced by more than one percent of the Issuer’s shares of Common Stock outstanding since the filing of the Original Schedule 13D.

 

Except as otherwise described herein, the information contained in the Original Schedule 13D remains in effect. Capitalized terms used but not defined in this Amendment shall have the respective meanings set forth with respect thereto in the Original Schedule 13D.

 

Item 2.

Identity and Background.

 

No changes except as described below.

 

(a) – (c) and (f) The name, business address, present principal occupation or employment and citizenship of the executive officers and members of the Board of Directors of each of the Reporting Persons is set forth on Schedule I hereto and is incorporated herein by reference.

 

(d) - (e) Neither the Reporting  Persons nor, to the best knowledge of each of them, any of the executive officers and members of the Board of Directors of each of the Reporting Persons set forth on Schedule I hereto during  the last  five  years,  (i) has been  convicted  in a criminal  proceeding  (excluding traffic violations or similar  misdemeanors) or (ii) was a party to a civil proceeding of a judicial or administrative  body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment,  decree or final order enjoining future violations of, or prohibiting or mandating  activities subject to, federal or state securities laws or finding any violation with respect to such laws.

 

Item 3.

Source and Amounts of Funds or Other Consideration.

 

No changes.

 

Item 4.

Purpose of Transaction.

 

No changes.

 

Item 5.

Interest in Securities of the Issuer.

 

No changes except as described below.

 

(a)       Based on 38,834,099 shares of Common Stock outstanding (which assumes no exercise of the underwriters’ option to purchase additional shares), as reported in the Issuer’s Prospectus Supplement filed with the SEC on June 26, 2018 pursuant to SEC Rule 424(b)(5), the Common Stock held by the Reporting Persons constitutes 14.95% of the outstanding shares of Common Stock of the Issuer.

 

(b)       With respect to the number of shares of Common Stock as to which each Reporting Person has:

 

(i)        sole power to vote or to direct the vote with respect to such shares of Common Stock, please see row 7 of the applicable cover sheet to this Amendment for such Reporting Person;

 

(ii)       shared power to vote or to direct the vote with respect to such shares of Common Stock, please see row 8 of the applicable cover sheet to this Amendment for such Reporting Person;

 

(iii)      sole power to dispose or direct the disposition of such shares of Common Stock, please see row 9 of the applicable cover sheet to this Amendment for such Reporting Person; and

 

CUSIP No. 00810B105

Schedule 13D

 

(iv)      shared power to dispose or to direct the disposition of such shares of Common Stock, please see row 10 of the applicable cover sheet to this Amendment for such Reporting Person.

 

(c)       Not applicable.

 

(d)       Not applicable.

 

(e)       Not applicable.

 

Item 6.

Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.

 

No changes.

 

Item 7.

Material to be Filed as Exhibits.

 

Exhibit Number

Description

 

99.1	Agreement regarding joint filing of Schedule 13D

 

CUSIP No. 00810B105

Schedule 13D

Signature

After reasonable inquiry and to the best of the undersigned’s knowledge and belief, the undersigned hereby certify that the information set forth in this statement is true, complete and correct.

	Date: July 9, 2018	NOVARTIS BIOVENTURES LTD.
		By:	/s/ Bart Dzikowski
		Name:	Bart Dzikowski
		Title:	Secretary of the Board
		By:	/s/ Stephan Sandmeier
		Name:	Stephan Sandmeier
		Title:	Authorized Signatory

 

		NOVARTIS AG
		By:	/s/ Bart Dzikowski
		Name:	Bart Dzikowski
		Title:	Authorized Signatory
		By:	/s/ Campbell Murray
		Name:	Campbell Murray
		Title:	Authorized Signatory

 

CUSIP No. 00810B105

Schedule 13D

 

DIRECTORS AND EXECUTIVE OFFICERS OF

NOVARTIS AG AND NOVARTIS BIOVENTURES LTD.

The name, function, citizenship and present principal occupation or employment of each of the directors and executive officers of Novartis AG are set forth below. Unless otherwise indicated below, (i) each occupation set forth opposite an individual’s name refers to employment with Novartis AG and (ii) the business address of each director and executive officer of Novartis AG is Novartis Campus, Lichtstrasse 35, CH-4056, Basel, Switzerland.

Name		Relationship to Novartis AG		Present Principal Occupation		Citizenship
Joerg Reinhardt, Ph.D.		Chairman of the Board of Directors		Chairman of the Board of Directors		German
Enrico Vanni, Ph.D.		Vice Chairman of the Board of Directors		Independent Consultant		Swiss
Nancy C. Andrews, M.D., Ph.D.		Director		Dean Emerita of the Duke University School of Medicine and Vice Chancellor Emerita for Academic Affairs at Duke University; Professor of Pediatrics, Pharmacology and Cancer Biology at Duke University		American
Dimitri Azar, M.D., MBA		Director		Senior Director of Ophthalmological Innovation at Verily Life Sciences; Dean of the College of Medicine and Professor of Ophthalmology, Bioengineering and Pharmacology at the University of Illinois		American
Ton Buechner		Director		Member of the Supervisory Board of Voith GmbH; Former CEO and Chairman of the executive board of AkzoNobel		Dutch
Srikant Datar, Ph.D.		Director		Arthur Lowes Dickinson Professor at the Graduate School of Business Administration at Harvard University		American
Elizabeth (Liz) Doherty		Director		Non-executive director and chairman of the audit committee of Dunelm Group plc; Member of the Supervisory Board and Audit Committee of Corbion NV		British

 

CUSIP No. 00810B105

Schedule 13D

 

Name

Relationship to Novartis AG

Present Principal Occupation

Citizenship

Ann Fudge		Director		Vice Chairman and Senior Independent Director of Unilever NV; Chair of the United States Program Advisory Panel of the Bill & Melinda Gates Foundation; Director of Northrop Grumman Corporation		American
Franz van Houten		Director		CEO and Chairman of the Executive Committee and the Board of Management of Royal Philips; Vice-Chairman and Member of the Supervisory Board of Philips Lighting		Dutch
Andreas von Planta, Ph.D.		Director		Board member of Helvetia Holding AG; Chairman of the Regulatory Board of the SIX Swiss Exchange AG		Swiss
Charles L. Sawyers, M.D.		Director		Chair of the Human Oncology and Pathogenesis Program at Memorial Sloan-Kettering Cancer Center; Professor of Medicine and of Cell and Developmental Biology at the Weill Cornell Graduate School of Medical Sciences; Investigator at the Howard Hughes Medical Institute		American
William T. Winters		Director		CEO and a board member of Standard Chartered		British
Vasant (Vas) Narasimhan, M.D.		Member of the Executive Committee; Chief Executive Officer		Member of the Executive Committee, Chief Executive Officer		American
Steven Baert		Member of the Executive Committee; Head of Human Resources		Member of the Executive Committee, Head of Human Resources		Belgian
Elizabeth (Liz) Barrett		Member of the Executive Committee; CEO, Novartis Oncology		Member of the Executive Committee; CEO, Novartis Oncology		American
Bertrand Bodson		Member of the Executive Committee; Chief Digital Officer		Member of the Executive Committee; Chief Digital Officer		Belgian

 

Name

Relationship to Novartis AG

Present Principal Occupation

Citizenship

James (Jay) Bradner, M.D.		Member of the Executive Committee; President, Novartis Institutes for BioMedical Research		Member of the Executive Committee; President, Novartis Institutes for BioMedical Research; 250 Massachusetts Avenue, Cambridge, MA 02139, USA		American
Richard Francis		Member of the Executive Committee; CEO, Sandoz		Member of the Executive Committee; CEO, Sandoz		British
Paul Hudson		Member of the Executive Committee; CEO, Novartis Pharmaceuticals		Member of the Executive Committee; CEO, Novartis Pharmaceuticals		British
Harry Kirsch		Member of the Executive Committee; Chief Financial Officer		Member of the Executive Committee; Chief Financial Officer		German
Shannon Thyme Klinger		Member of the Executive Committee; Group General Counsel		Member of the Executive Committee; Group General Counsel		American
Steffen Lang, Ph.D.		Member of the Executive Committee; Global Head of Novartis Technical Operations		Member of the Executive Committee; Global Head of Novartis Technical Operations		German
John Tsai, M.D.		Member of the Executive Committee; Head of Global Drug Development and Chief Medical Officer		Member of the Executive Committee; Head of Global Drug Development and Chief Medical Officer		American
Robert Weltevreden		Member of the Executive Committee; Head of Novartis Business Services		Member of the Executive Committee; Head of Novartis Business Services		Dutch

 

CUSIP No. 00810B105

Schedule 13D

 

The name, address, citizenship and present principal occupation or employment of each of the directors and executive officers of Novartis Bioventures Ltd. are set forth below. Unless otherwise indicated below, (i) each occupation set forth opposite an individual’s name refers to employment with Novartis Bioventures Ltd. and (ii) the business address of each director and executive officer of Novartis Bioventures Ltd. is Novartis Campus, Lichtstrasse 35, CH-4056, Basel, Switzerland.

Name		Relationship to Novartis Bioventures Ltd.		Present Principal Occupation		Citizenship
Prof. Dr. Patrick Aebischer		Chairman of the Board of Directors		President emeritus of the École Polytechnique Fédérale de Lausanne (EPFL); Member of the Board of Directors at Lonza AG, Nestlé S.A. and Logitech International S.A.		Swiss
Dr. Paul Herrling		Director		Vice-President of the Board of the Swiss Federal Institutes of Technology (ETH Rat); Professor for Drug Discovery Science at the University of Basel		Swiss
Harry Kirsch		Director		Member of the Executive Committee of Novartis; Chief Financial Officer at Novartis		German
Prof. Dr. Christoph Meier		Director		Chief Medical Officer at the University Hospital Basel; Professor at the Medical Faculty of the University of Geneva		Swiss
Dr. Raj Parekh		Director		General Partner at Advent Life Sciences		British

 

---